JP2008526861A - 炎症性障害を治療するための薬剤併用療法および医薬組成物 - Google Patents

炎症性障害を治療するための薬剤併用療法および医薬組成物 Download PDF

Info

Publication number
JP2008526861A
JP2008526861A JP2007550445A JP2007550445A JP2008526861A JP 2008526861 A JP2008526861 A JP 2008526861A JP 2007550445 A JP2007550445 A JP 2007550445A JP 2007550445 A JP2007550445 A JP 2007550445A JP 2008526861 A JP2008526861 A JP 2008526861A
Authority
JP
Japan
Prior art keywords
cyclopentyl
trifluoromethyl
isopropyl
statin
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007550445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526861A5 (https=
Inventor
フオレスト，マイケル・ジエイ
デマルテイーノ，ジユリー・エイ
フリツカー，ミシエル・アール
メリアン，オーガステイン
カンワル，サミナ
ロマノ，ゲイリー・ジエイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2008526861A publication Critical patent/JP2008526861A/ja
Publication of JP2008526861A5 publication Critical patent/JP2008526861A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007550445A 2005-01-06 2006-01-05 炎症性障害を治療するための薬剤併用療法および医薬組成物 Withdrawn JP2008526861A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64170705P 2005-01-06 2005-01-06
PCT/US2006/000253 WO2006074265A2 (en) 2005-01-06 2006-01-05 Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders

Publications (2)

Publication Number Publication Date
JP2008526861A true JP2008526861A (ja) 2008-07-24
JP2008526861A5 JP2008526861A5 (https=) 2009-02-19

Family

ID=36648157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007550445A Withdrawn JP2008526861A (ja) 2005-01-06 2006-01-05 炎症性障害を治療するための薬剤併用療法および医薬組成物

Country Status (7)

Country Link
US (1) US20080194548A1 (https=)
EP (1) EP1855673A4 (https=)
JP (1) JP2008526861A (https=)
CN (1) CN101098700A (https=)
AU (1) AU2006204038A1 (https=)
CA (1) CA2593545A1 (https=)
WO (1) WO2006074265A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004231087B2 (en) * 2003-04-15 2007-01-04 Merck Sharp & Dohme Corp. Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
AU2007336118A1 (en) * 2006-12-18 2008-06-26 Cardoz Ab New combination for use in the treatment of inflammatory disorders
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
WO2012125663A2 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Cyclohexane substituted amino cyclopentane derivatives as useful ccr2 antagonists
DK3297438T3 (da) 2015-05-21 2022-01-17 Chemocentryx Inc Ccr2-modulatorer
CA3293051A1 (en) 2017-09-25 2026-03-02 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN112105353B (zh) 2018-01-08 2024-04-19 凯莫森特里克斯股份有限公司 Ccr2拮抗剂治疗实体瘤的方法
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
US20230270732A1 (en) * 2022-02-28 2023-08-31 University Of South Florida Blockade of chemokine (c-c motif) receptor 2 during fluid resuscitation
CN119925562B (zh) * 2023-11-03 2025-11-28 中国科学院上海药物研究所 趋化因子受体2拮抗剂在制备治疗糖尿病并发焦虑症的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4342767A (en) * 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5311116A (en) * 1992-04-02 1994-05-10 Electronic Development, Inc. Multi-channel electromagnetically transparent voltage waveform monitor link
CZ288545B6 (cs) 1995-12-22 2001-07-11 Kowa Company, Ltd. Stabilizovaná farmaceutická kompozice na bázi kyseliny (E)-3,5-dihydroxy-7-[4´-4´´-fluorfenyl-2´-cyklopropylchinolin-3´-yl]-6-heptenové
JPH11243960A (ja) * 1998-03-06 1999-09-14 Shionogi & Co Ltd ヒトｃｃ型ケモカインエオタキシン３
WO2002050019A2 (en) * 2000-12-20 2002-06-27 Bristol-Myers Squibb Pharma Co. Diamines as modulators of chemokine receptor activity
EP1501507B1 (en) * 2002-04-29 2008-05-28 Merck & Co., Inc. Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
AU2004231087B2 (en) * 2003-04-15 2007-01-04 Merck Sharp & Dohme Corp. Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
US7163945B2 (en) * 2004-04-29 2007-01-16 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase

Also Published As

Publication number Publication date
CN101098700A (zh) 2008-01-02
EP1855673A4 (en) 2008-03-12
EP1855673A2 (en) 2007-11-21
WO2006074265A2 (en) 2006-07-13
AU2006204038A1 (en) 2006-07-13
WO2006074265A3 (en) 2007-06-14
US20080194548A1 (en) 2008-08-14
CA2593545A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
JP2008526861A (ja) 炎症性障害を治療するための薬剤併用療法および医薬組成物
AU2016233257B2 (en) Fixed dose combinations comprising ETC1002 and one or more statins for treating or reducing cardiovascular risk
JP2002322095A (ja) 脳卒中及び外傷性脳損傷の治療のための医薬としての組み合わせ
JPH06500078A (ja) Ｔｎｆ抑制剤
JP2020507610A (ja) 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法
JP2017522270A (ja) 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン
WO2015051327A1 (en) Treating inflammation using llp2a-bisphosphonate conjugates and mesenchymal stem cells
AU2007206776A1 (en) Methods
US9044427B2 (en) Compositions and methods for prevention and treatment of wounds
JP2010513430A (ja) 炎症障害の治療において使用するための新たな併用
TW200306853A (en) Therapeutic agent for glomerular disease
JPH1192382A (ja) 細胞接着阻害剤
JP4409295B2 (ja) Ｐｔｘ３遺伝子発現抑制方法
US20140127295A1 (en) Compositions, process of preparation of said compositions and method of treating inflammatory diseases
CN116473966B (zh) Sb-222200在抑制nlrp3炎症小体活化中的应用
EP4511031A1 (en) Treatment of neutrophilic dermatoses
KR101258422B1 (ko) 신규의 트리글리세리드 저하제
CN1177296A (zh) TNF－α抑制剂
CN115461047A (zh) 用于治疗细胞因子风暴的组合物和方法
RU2721282C2 (ru) Способ лечения рассеянного склероза (варианты)
WO2026006510A1 (en) Compounds as nlrp3 inhibitors, and compositions and uses thereof
WO2026006505A1 (en) Compounds as nlrp3 inhibitors and compositions and uses thereof
Duplantier et al. Novel pharmacological approaches to the treatment of asthma: status and potential of therapeutic classes
WO2005089762A2 (en) Pharmaceutical composition of (+)-erythro-mefloquine and its use in the treatment of an inflammatory condition
CN101534825A (zh) 含有贝特类药物的制剂及其制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081222

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20091203